Certain drug combinations such as temozolomide and lomustine have increased the overall survival by six months in phase III clinical trials in newly diagnosed GBM patients with O6-Methylguanine-DNA Methyltransferase (MGMT) methylation [29]. This evidence concerns the gene MGMT and glioblastoma.